Attralus
South San Francisco, US · Founded 2019 · Delaware corporation · 4 known investors
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.
BiotechHealthtech
Founders & leadership
Attralus was founded in 2019 by Jonathan Wall.
JW
Jonathan WallFounder
SG
Spencer GuthrieExecutive
MT
Mark TimneyExecutive
BF
Benson FongNamed on SEC filing
RK
Rahul KakkarNamed on SEC filing
GB
Greg BellNamed on SEC filing
JB
Jake BauerNamed on SEC filing
Board
AD
Alex DennerBoard director
RG
CG
NM
Nancy Miller-RichBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$172.8M disclosed across 3 rounds · 2019–2024
▶$56MraisedFeb 2024 · 12 investors · BiotechnologyRule 506(b)
▶$56MraisedFeb 2024 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark TimneyExecutive Officer, Director
- Richard GasterDirector
- Mehdi KhodadadExecutive Officer
- Corey GoodmanDirector
- Glen FirestoneExecutive Officer
- Rahul KakkarDirector
- Gregory BellExecutive Officer
- Spencer GuthrieExecutive Officer
- James TestaExecutive Officer
- Jake BauerDirector
- Nancy Miller-RichDirector
- Alex DennerDirector
- Offering amount
- $56M
- Amount sold
- $56M
- Minimum investment
- $24.4K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$116.6MraisedSep 2021 · 22 investors · BiotechnologyRule 506(b)
▶$116.6MraisedSep 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benson FongExecutive Officer
- Rahul KakkarDirector
- Greg BellExecutive Officer
- Jake BauerDirector
- Spencer GuthrieExecutive Officer
- Alex DennerDirector
- Richard GasterDirector
- Nancy Miller-RichDirector
- Mark TimneyExecutive Officer, Director
- Corey GoodmanDirector
- Jonathan WallExecutive Officer
- Offering amount
- $116.6M
- Amount sold
- $116.6M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$175KraisedDec 2019 · 5 investors · BiotechnologyRule 506(b)
▶$175KraisedDec 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan WallDirector
- Spencer GuthrieExecutive Officer, Director
- Amount sold
- $175K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapTrisaluslifesci26 shared keywordsTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Applied Therapeutics16 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.
Talus Bio15 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Attralus for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Attralus do?
- Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.
- Who founded Attralus?
- Attralus was founded by Jonathan Wall in 2019.
- Who are Attralus's investors?
- Attralus's investors include Alpha Wave Global, BioBrit, venBio Partners, venBio Global Strategic.
- How much funding has Attralus raised?
- Attralus has disclosed $172.8M raised across 3 rounds.
- Where is Attralus headquartered?
- Attralus is headquartered in South San Francisco, US.